Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04532606 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Impact of Remimazolam on Prognosis After Bladder Cancer Surgery

StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated July 30, 2025 (before its estimated October 2025 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Oct 2024 to Oct 2025
    • Study completion date: Oct 2025 to Oct 2026
    v7
  2. Primary completion date: Oct 2022 to Oct 2024
    • Study completion date: Oct 2023 to Oct 2025
    v6
  3. Study sites: 1 to 6
    • Collaborators expanded, about 21 words
    v5
  4. Eligibility criteria expanded, about 5 wordsv4
  5. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jan 2021 to Feb 5, 2021
    • Site details revised
    v3
  6. Start date: Oct 2020 to Jan 2021v2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Bladder cancer is one of the most common genitourinary cancers. Transurethral resection of bladder tumor (TURBT) is the standard therapy for nonmuscle invasive bladder cancer. However, patients after TURBT are at risk for recurrence and progression. Benzodiazepines are proved to inhibit proliferation of multiple types of cancer cells in vitro. Delirium is an acute onset and transient cerebral dysfunction and is associated with worse outcomes. Previous studies indicated that benzodiazepines increase incidence of postoperative delirium. Remimazolam is a new benzodiazepine with rapid onset and ultra-short activity. The aims of this study are to explore the impact of remimazolam for general anesthesia on emergency delirium and recurrence-free survival in patients undergoing bladder cancer surgery.
Trial Details
NCT Number NCT04532606
Lead Sponsor Peking University First Hospital
Collaborators: Beijing Tsinghua Chang Gung Hospital, Navy General Hospital, Beijing, Guizhou Provincial People's Hospital, Jiangsu Provincial People's Hospital, Shanghai 10th People's Hospital
Conditions
(from sponsor)		 Benzodiazepines, Bladder Cancer, Delirium, Surgery, Cancer Recurrence
Related terms Delirium, Emergence Delirium, Urinary Bladder Neoplasms
Enrollment 1,128 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov